Cargando…
The clinical evidence for postbiotics as microbial therapeutics
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concern...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542959/ https://www.ncbi.nlm.nih.gov/pubmed/36184735 http://dx.doi.org/10.1080/19490976.2022.2117508 |
_version_ | 1784804264807235584 |
---|---|
author | Mosca, Alexis Abreu Y Abreu, Ana Teresa Gwee, Kok Ann Ianiro, Gianluca Tack, Jan Nguyen, Thi Viet Ha Hill, Colin |
author_facet | Mosca, Alexis Abreu Y Abreu, Ana Teresa Gwee, Kok Ann Ianiro, Gianluca Tack, Jan Nguyen, Thi Viet Ha Hill, Colin |
author_sort | Mosca, Alexis |
collection | PubMed |
description | An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy. |
format | Online Article Text |
id | pubmed-9542959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-95429592022-10-08 The clinical evidence for postbiotics as microbial therapeutics Mosca, Alexis Abreu Y Abreu, Ana Teresa Gwee, Kok Ann Ianiro, Gianluca Tack, Jan Nguyen, Thi Viet Ha Hill, Colin Gut Microbes Review An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy. Taylor & Francis 2022-10-02 /pmc/articles/PMC9542959/ /pubmed/36184735 http://dx.doi.org/10.1080/19490976.2022.2117508 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Mosca, Alexis Abreu Y Abreu, Ana Teresa Gwee, Kok Ann Ianiro, Gianluca Tack, Jan Nguyen, Thi Viet Ha Hill, Colin The clinical evidence for postbiotics as microbial therapeutics |
title | The clinical evidence for postbiotics as microbial therapeutics |
title_full | The clinical evidence for postbiotics as microbial therapeutics |
title_fullStr | The clinical evidence for postbiotics as microbial therapeutics |
title_full_unstemmed | The clinical evidence for postbiotics as microbial therapeutics |
title_short | The clinical evidence for postbiotics as microbial therapeutics |
title_sort | clinical evidence for postbiotics as microbial therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542959/ https://www.ncbi.nlm.nih.gov/pubmed/36184735 http://dx.doi.org/10.1080/19490976.2022.2117508 |
work_keys_str_mv | AT moscaalexis theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT abreuyabreuanateresa theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT gweekokann theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT ianirogianluca theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT tackjan theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT nguyenthivietha theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT hillcolin theclinicalevidenceforpostbioticsasmicrobialtherapeutics AT moscaalexis clinicalevidenceforpostbioticsasmicrobialtherapeutics AT abreuyabreuanateresa clinicalevidenceforpostbioticsasmicrobialtherapeutics AT gweekokann clinicalevidenceforpostbioticsasmicrobialtherapeutics AT ianirogianluca clinicalevidenceforpostbioticsasmicrobialtherapeutics AT tackjan clinicalevidenceforpostbioticsasmicrobialtherapeutics AT nguyenthivietha clinicalevidenceforpostbioticsasmicrobialtherapeutics AT hillcolin clinicalevidenceforpostbioticsasmicrobialtherapeutics |